Shancai Xu

Dr. Shancai Xu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Autonomic Neuroscience
Verified
Journal Article
Closed access
GCGao Cheng
Gao Cheng
XLXiangzhen Liu
Xiangzhen Liu
HSHuaizhang Shi
Huaizhang Shi
SXShancai Xu
Shancai Xu
ZJzhi-yong ji
zhi-yong ji
SZShiguang Zhao
Shiguang Zhao

1 February 2019 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
PWPei Wu
Pei Wu
PEPınar Eser
Pınar Eser
DWDianhong Wang
Dianhong Wang
UOUmut Ocak
Umut Ocak
SXShancai Xu
Shancai Xu
HSHuaizhang Shi
Huaizhang Shi

15 November 2014 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
SXShancai Xu
Shancai Xu
PWPei Wu
Pei Wu
HSHuaizhang Shi
Huaizhang Shi
ZJZhiyong Ji
Zhiyong Ji
JDJiaxing Dai
Jiaxing Dai

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JDJiaxing Dai
Jiaxing Dai
SXShancai Xu
Shancai Xu
TOTakeshi Okada
Takeshi Okada
YLyu liu
yu liu
GZGang Zuo
Gang Zuo
HSHuaizhang Shi
Huaizhang Shi
Background and Purpose. T0901317, a liver X receptor (LXR) agonist, is widely used to explore the functions of LXRs. T0901317 exerts antiapoptotic effects in many central nervous system disease models. Our aim was to detect the role of T0901317 in neuronal apoptosis in early brain injury after subarachnoid hemorrhage. Methods. Subarachnoid hemorrhage (SAH) models of Sprague‐Dawley rats were established with perforation method. T0901317 was injected intraperitoneally 1‐hour post‐SAH. GSK2033, an inhibitor of LXRs, and interferon regulatory factor (IRF‐1) CRISPR activation were injected intracerebroventricularly to evaluate potential signaling pathway. The severity of SAH, neurobehavior test in both short‐ and long‐term and apoptosis was measured with Western blot and immunofluorescence staining. Results. Expression of LXR‐α and IRF‐1 increased and peaked at 24 h post‐SAH, while LXR‐β remained unaffected in SAH+vehicle group compared with Sham group. Post‐SAH T0901317 treatment attenuated neuronal impairments in both short‐ and long‐term and decreased neuronal apoptosis, the expression of IRF‐1, P53 upregulated modulator of apoptosis (PUMA), dynamin‐1‐like protein (Drp1), Bcl‐2‐associated X protein (Bax) and cleaved caspase‐3, and increasing B‐cell lymphoma 2 (Bcl‐2) at 24 h from modeling. GSK2033 inhibited LXRs and reversed T0901317’s neuroprotective effects. IRF‐1 CRISPR activation upregulated the expression of IRF‐1 and abolished the treatment effects of T0901317. Conclusion. T0901317 attenuated neuronal apoptosis via LXRs/IRF‐1/PUMA/Drp1 pathway in SAH rats.

24 September 2024 in Brain Research Bulletin
Verified
Journal Article
Open access
JYJinshuo Yang
Jinshuo Yang
QWQiaowei Wu
Qiaowei Wu
SLShuai Lan
Shuai Lan
KYKaikun Yuan
Kaikun Yuan
BSBowen Sun
Bowen Sun
HSHuaizhang Shi
Huaizhang Shi
Following subarachnoid haemorrhage (SAH), excessive activation of oxidative stress and cell apoptosis plays a critical role in early brain injury (EBI). Peroxiredoxin-5 (Prdx5), predominantly expressed in neuronal mitochondria, acts as an antioxidant. However, the role of Prdx5 in EBI after SAH remains unclear. This study aims to elucidate the antioxidative stress and anti-apoptotic effects of Prdx5 in rats following SAH. In this study, an SAH model was established in Sprague-Dawley rats using endovascular perforation. Recombinant Prdx5 (rPrdx5) was administered intraperitoneally to upregulate Prdx5 expression after SAH in rats. Prdx5 small interfering RNA (Prdx5 siRNA) was administered prior to SAH modelling. The neuroprotective effects of Prdx5 were validated through SAH grading, brain water content, blood-brain barrier permeability, neurobehavioral tests, immunofluorescence, TUNEL staining, and Western blotting. The expression levels of endogenous Prdx5 significantly decreased after SAH. Treatment with rPrdx5 improved both short-term and long-term behaviour in rats, reduced brain water content and blood-brain barrier permeability, and exhibited anti-oxidative stress and anti-apoptotic effects. Measurements of oxidative stress-related indicators, including MDA, GSH-Px, SOD, and GSH/GSSG, confirmed that Prdx5 can alleviate oxidative stress in rats after SAH. Western blot analysis showed that rPrdx5 significantly increased the expression of Bcl-XL and Bcl-2 and reduced the expression of Bax and Cleaved Caspase-3, thereby exerting anti-apoptotic effects. Additionally, Prdx5 siRNA reversed the neuroprotective effects of rPrdx5, exacerbated neuronal damage and blood-brain barrier permeability, and increased levels of oxidative stress and apoptosis. In conclusion, our study demonstrated that specifically upregulating the expression of Prdx5 can reduce oxidative stress and apoptosis in rats after SAH, while also improving both short-term and long-term neurological impairments. Prdx5 is primarily expressed in the mitochondria of neuronal cells and is a crucial target for reducing ROS after SAH. rPrdx5 treatment may offer a promising therapeutic approach for clinical SAH patients.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BSBowen Sun
Bowen Sun
CXChao Xu
Chao Xu
PWPei Wu
Pei Wu
MLMan Li
Man Li
SXShancai Xu
Shancai Xu
HSHuaizhang Shi
Huaizhang Shi
Background. The high rate of periprocedural complications for the endovascular stent procedure in the Stenting Versus Aggressive Medical Management Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial resulted in it being less recommended than medical therapy to treat intracranial atherosclerotic stenosis (ICAS). Because Enterprise stent use might reduce the incidence of complications in ICAS treatment compared to other frequently used stents, this paper evaluated the safety and effectiveness of the Enterprise stent for the treatment of ICAS. Methods. We performed a comprehensive literature search for reports on intracranial angioplasty using the Enterprise stent for ICAS treatment from the earliest date available from each database to May 2020 for PubMed, EMBASE, Web of Science, Cochrane, and Clinical Trials databases. We also reviewed the single‐center experience of the First Affiliated Hospital of Harbin Medical University. We extracted information regarding periprocedural complications, procedure‐related morbidity, mortality, immediate angiographic outcome, and long‐term clinical and angiographic outcomes, among others. Event rates were pooled across studies using random‐effects or fixed‐effects models depending on the heterogeneity. Results. Five hundred fifty‐seven patients with 588 lesions from seven studies, including the institutional series, were included in the analysis. The incidence of stroke or death within 30 days was 7.4% (95% confidence interval (CI), 5.5%–10.1%). The incidence of ischemic stroke or TIA in the territory of the qualifying artery beyond 30 days and during follow‐up was 3.2% (95% CI, 1.1%–9.5%). The incidence of in‐stent restenosis was 10.1% (95% CI, 4.6%–22.2%), and the incidence of symptomatic restenosis was 4.1% (95% CI, 1.7%–9.9%). Conclusions. Intracranial angioplasty utilizing the Enterprise stent for ICAS treatment was relatively safe and effective but required further verification using additional sources for evidence.